Apothecon To Continue As Bristol Unit After Sale Of Generics To Novartis

Bristol Myers-Squibb will continue to market generic drugs internationally and its branded generics in the U.S. following the sale of U.S. rights to its Apothecon subsidiary's line of finished generic drugs to Novartis.